RxDoctor Payments Data

Anna Kim, MD

Internal Medicine · Nipomo, CANPI 1588682769

Payments from drug & device makers

$532in general payments, 2019–2025

Across 41 payments — averaging $12.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$144
  • Sunovion Pharmaceuticals Inc.$48
  • Sanofi-aventis U.S. LLC$44
  • Lilly USA, LLC$41
  • Takeda Pharmaceuticals U.S.A., Inc.$30
  • Amgen$29
  • plus $197 from 11 others

What the payments were for

  • Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$108,932
Medicare patients
423
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$75,333
OzempicSemaglutide46$56,607
JardianceEmpagliflozin34$47,911
XareltoRivaroxaban33$36,176
JanuviaSitagliptin Phosphate23$30,414
TrulicityDulaglutide14$22,209
MounjaroTirzepatide15$15,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,770
MyrbetriqMirabegron18$13,934
Repatha SyringeEvolocumab11$6,028
Breo ElliptaFluticasone/Vilanterol14$5,509
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,187
Levothyroxine Sodium340$3,314
SynthroidLevothyroxine Sodium54$3,284
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$144$75,33379 claims
Boehringer IngelheimJardiance$20$47,91134 claims
Lilly USA, LLCTrulicity, Mounjaro$41$37,89129 claims
Johnson & JohnsonXarelto$19$36,17633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Nipomo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →